ProKidney Corp reports results for the quarter ended in March - Earnings Summary

Prokidney

10/05/2024 15:25

* ProKidney Corp  PROK.OQ  reported a quarterly adjusted
loss
of 16 cents​​ per share for the quarter ended in March,
identical to the same quarter last year.  The lone analyst
forecast for the quarter was for a loss of 18 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * ProKidney Corp's reported EPS for the quarter was a loss
of 16
cents​.
    * The company reported a quarterly loss of $9.49 million.
    * ProKidney Corp shares had risen by 59.1% this quarter and
gained 46.6% so far this year.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for ProKidney Corp is
$5.00 
This summary was machine generated from LSEG data May 10 at
02:24 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.18          -0.16          Beat
 Dec. 31 2023      -0.17          -0.09          Beat
 Sep. 30 2023      -0.16          -0.18          Missed
 Jun. 30 2023      -0.39          -0.14          Beat